Full Press Release Details
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc.(Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update.
“Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in the second quarter of 2026,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We are focused on the regulatory, manufacturing, and commercial readiness activities necessary to position the program for approval and launch.”
“We continue to advance our antibody-drug conjugate pipeline, with the Phase 1 study of IM-1021 ongoing. Over the course of 2026, we expect to submit INDs for three differentiated solid tumor ADCs. These programs have substantial potential to benefit cancer patients, and we intend to rapidly advance them.”
Pipeline Highlights
Varegacestat:
IM-1021: The Phase 1 clinical trial of IM-1021 is ongoing, with objective responses observed in B-cell lymphoma patients at multiple dose levels. Immunome expects to present initial data for IM-1021 in 2026.
IM-3050: Immunome previously received IND clearance for IM-3050 and plans to initiate a Phase 1 study in early 2026 after delivery of third-party diagnostic radiotracer supply.
Preclinical ADC Pipeline: Immunome expects to submit INDs for IM-1617, IM-1340 and IM-1335 in early, mid, and late-2026, respectively. The programs each pursue undisclosed solid tumor targets and incorporate HC74, Immunome’s proprietary TOP1 inhibitor payload. Additional undisclosed antibody drug conjugates (ADCs) are in discovery and lead optimization to support INDs in 2027 and beyond.
HC74: In October 2025, Immunome presented a poster entitled “HC74, a novel topoisomerase I inhibitor payload for antibody-drug conjugates that overcomes multi-drug resistance” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. HC74 is the payload included in IM-1021 and additional Immunome ADC programs. Highlights of the poster include:
Full-year 2025 Financial Results
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage gamma secretase inhibitor; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “planned,” “expected,” “focused,” “advance,” “projected,” “will,” “potential,” “expect,” “intend,” “plan,” “pursue,” “support,” “expects,” “advancing,” and similar expressions to identify these forward-looking statements. These forward-looking statements include statements regarding progress of Immunome’s pipeline and achievement of key milestones; the timing for submission of a new drug application for varegacestat; the possibility that topline data for the Phase 3 RINGSIDE Part B varegacestat trial may support the new drug application submission; the potential of obtaining regulatory approval and our ability to launch of varegacestat; the significance of early clinical trial data for IM-1021; the potential of Immunome’s proprietary payload; Immunome’s progress towards submitting INDs for three additional ADCs; the expected timing for initiating a Phase 1 clinical trial for IM-3050; Immunome’s expected cash runway; the potential of Immunome’s targeted therapies to provide first-in-class or best-in-class status; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the risk that Immunome will not be able to realize the benefits of its strategic transactions; the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data or that early clinical data may not be predictive of later clinical data, regulatory approval or commercial viability; the risk of reliance on third-party vendors; the risk that Immunome’s programs and product candidates fail to achieve their intended endpoints; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; Immunome’s ability to grow and advance its pipeline and successfully execute on its business plan; and other risks and uncertainties included under the caption “Risk Factors” in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 6, 2025, and in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2025, to be filed with the SEC later today. These documents can also be accessed on Immunome’s website atwww.immunome.comby clicking on the link “Financials” under the “Investors” tab. The forward-looking statements included in this press release are made only as of the date hereof. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
| IMMUNOME, INC. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (In thousands) | ||||||||
| December 31, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 653,482 | $ | 143,351 | ||||
| Marketable securities | — | 73,952 | ||||||
| Prepaid expenses and other current assets | 7,295 | 4,036 | ||||||
| Total current assets | 660,777 | 221,339 | ||||||
| Property and equipment, net | 14,636 | 10,113 | ||||||
| Operating right-of-use assets | 2,978 | 4,278 | ||||||
| Restricted cash | 210 | 100 | ||||||
| Other long-term assets | 4,587 | 4,411 | ||||||
| Total assets | $ | 683,188 | $ | 240,241 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,339 | $ | 14,189 | ||||
| Accrued expenses and other current liabilities | 41,651 | 33,177 | ||||||
| Deferred revenue, current | — | 6,941 | ||||||
| Total current liabilities | 44,990 | 54,307 | ||||||
| Operating lease liabilities, net of current portion | 3,855 | 4,769 | ||||||
| Total liabilities | 48,845 | 59,076 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 11 | 6 | ||||||
| Additional paid-in capital | 1,362,496 | 696,872 | ||||||
| Accumulated other comprehensive income | — | 57 | ||||||
| Accumulated deficit | (728,164 | ) | (515,770 | ) | ||||
| Total stockholders’ equity | 634,343 | 181,165 | ||||||
| Total liabilities and stockholders’ equity | $ | 683,188 | $ | 240,241 | ||||
| IMMUNOME, INC. | ||||||||
| Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Collaboration revenue | $ | 6,941 | $ | 9,041 | ||||
| Operating expenses: | ||||||||
| In-process research and development | 10,000 | 152,344 | ||||||
| Research and development(1) | 177,286 | 129,542 | ||||||
| General and administrative(1) | 43,768 | 32,955 | ||||||
| Total operating expenses | 231,054 | 314,841 | ||||||
| Loss from operations | (224,113 | ) | (305,800 | ) | ||||
| Interest income | 11,719 | 12,837 | ||||||
| Net loss | $ | (212,394 | ) | $ | (292,963 | ) | ||
| Net loss per share, basic and diluted | $ | (2.43 | ) | $ | (5.00 | ) | ||
| Weighted-average shares outstanding, basic and diluted | 87,350,956 | 58,639,441 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (212,394 | ) | $ | (292,963 | ) | ||
| Unrealized (loss) gain on marketable securities | (57 | ) | 35 | |||||
| Comprehensive loss | $ | (212,451 | ) | $ | (292,928 | ) | ||
| (1) Amounts include non-cash share-based compensation as follows (in thousands): | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development | $ | 11,193 | $ | 5,146 | ||||
| General and administrative | 14,497 | 10,602 | ||||||
| Total share-based compensation expense | $ | 25,690 | $ | 15,748 |